Palindromic Rheumatism
The exact cause of palindromic rheumatism (PR) is believed to involve a complex interplay between autoimmunity and autoinflammation. Our company is proud to be at the forefront of PR drug and therapy development. Our multidisciplinary team of experts is dedicated to advancing the field and bringing innovative solutions to pharmaceutical companies in need.
Introduction to Palindromic Rheumatism
Palindromic rheumatism (PR) is a rare form of inflammatory arthritis characterized by recurrent episodes of joint pain and swelling that typically last for 24-36 hours. The affected joints commonly include the wrists, metacarpophalangeal joints, shoulders, and ankles. Research has shown that a significant number of PR cases exhibit a serum autoantibody profile similar to that of rheumatoid arthritis (RA). Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) are frequently present in PR cases, often at high titers. This suggests a potential connection between PR and RA, with some cases even showing a progression to persistent polyarthritis.
Fig.1 Palindromic rheumatism and the rheumatoid arthritis (RA) disease continuum. (Mankia K., et al., 2019)
Therapy Discovery and Development for Palindromic Rheumatism
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to alleviate acute PR attacks, although their efficacy may vary among individuals. Hydroxychloroquine is currently considered the drug of choice for PR, as it has been shown to reduce the frequency and intensity of attacks. It may also delay the progression to RA, although it may not entirely prevent it. Furthermore, rituximab, a monoclonal antibody targeting B cells, has shown promising response rates in some PR cases, indicating the potential role of B cell modulation in PR therapeutics.
Our company aims to contribute to the development of diagnostics and novel therapies for PR by conducting rigorous research and preclinical trials. You can click on the links below to learn more about our therapy development services.
Our Services
Our therapy development services focus on advancing the understanding of PR. Through preclinical research, we strive to unravel the underlying mechanisms of PR and identify potential therapeutic targets. Our team of experts specializes in developing animal models and in vitro models that mimic the characteristics of PR, enabling us to test the efficacy and safety of potential drug candidates.
Induced Animal Models
A widely employed animal model for studying rheumatoid arthritis (RA) is the collagen-induced arthritis (CIA) model in mice. This particular model involves the immunization of mice with collagen, which triggers an immune response, ultimately leading to the development of arthritis-like symptoms.
We provide a comprehensive cell-based models development service that encompasses the isolation and cultivation of pertinent cell types essential for creating robust and representative in vitro models, including synovial fibroblasts, immune cells, and endothelial cells.
Organoid models aim to recreate the three-dimensional (3D) structure and functionality of organs or tissues. Our company offers an organoid model development service, enabling the generation of PR-specific organoids that replicate the cellular composition and interactions found in affected tissues.
At our company, we are proud to be at the forefront of PR drug and therapy development. Beyond the aforementioned repertoire of services and models, our expertise extends to crafting personalized solutions and designing disease models that impeccably align with your unique needs. If our comprehensive range of offerings has piqued your interest, we wholeheartedly encourage you to connect with us without any hesitation.
References
- Mankia Kulveer, and Paul Emery. "Palindromic rheumatism as part of the rheumatoid arthritis continuum." Nature Reviews Rheumatology 15.11 (2019): 687-695.
- Sanmartí Raimon, et al. "Palindromic rheumatism: just a pre-rheumatoid stage or something else?." Frontiers in medicine 8 (2021): 657983.